We investigated the mechanism of intrinsic resistance to cisplatin in human transitional cell cancer (TCC) using 7 human bladder cancer cell lines, which were derived from untreated TCC of the urinary bladder. The sensitivity to cisplatin was different from cell line to cell line, and a 15-fold difference was observed between the most sensitive line and the most resistant line. No significant correlation was observed between the content of intracellular glutathione and the resistance to cisplatin. In contrast, a positive correlation was seen between intracellular cisplatin accumulation and cisplatin resistance. The expression of drug resistance-related genes including glutathione S-transferase pi, gamma-glutamyl-cysteine synthetase, multidrug resistance-1, multidrug resistance-associated protein, DNA topoisomerase I, topoisomerase II, human canalicular multispecific organic anion transporter, and thioredoxin was not significantly related to cisplatin resistance. These data suggest that intracellular cisplatin may contribute to intrinsic cisplatin resistance and may therefore be a useful biomarker to predict cisplatin sensitivity in human untreated TCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3892/ijo.16.5.1003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CSF1R inhibition agents protect against cisplatin ototoxicity and synergize with immunotherapy for Head and Neck Squamous Cell Carcinoma.
Int Immunopharmacol
March 2025
Department of Otolaryngology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China. Electronic address:
Immunotherapy has emerged as a promising therapeutic approach. However, limited research exists on combining cisplatin with CSF1/CSF1R immunotherapy in Head and Neck Squamous Cell Carcinoma. Furthermore, few studies have investigated concurrent immunotherapeutic strategies to mitigate cisplatin-induced ototoxicity.
View Article and Find Full Text PDFA machine learning-based prognostic signature utilizing MSC proteomics for predicting bladder cancer prognosis and treatment response.
Transl Oncol
March 2025
Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu Province for Urological Diseases, Gansu Urological Clinical Center, Lanzhou, China. Electronic address:
Background: Mesenchymal stem cells (MSCs), due to their tumor-targeting homing properties, are present in the tumor microenvironment (TME) and influence the biological behaviors of tumors. The purpose of this paper is to establish a signature based on the MSC secretome to predict the prognosis and treatment of bladder cancer (BLCA).
Methods: The presence of MSCs in BLCA was validated through flow cytometry and multiplex fluorescence immunohistochemistry (mFIHC), and the relationships between MSCs and clinical characteristics were explored.
Green Synthesis of Silver Nanoparticles: Enhancing Cisplatin Binding to Biomolecules for Improved Drug Delivery and Therapeutic Synergy.
Microsc Res Tech
March 2025
Faculty of Science and Marine Environment, Universiti Malaysia Terengganu, Kuala Terengganu, Malaysia.
Cisplatin and other anticancer drugs face challenges such as systemic toxicity and drug resistance, necessitating novel delivery strategies. Nanoparticles have revolutionized drug delivery by enhancing the efficacy and bioavailability of therapeutic agents. In this study, silver nanoparticles (AgNPs) were green-synthesized using Chromolaena odorata (CO) and characterized using UV-Vis spectroscopy, Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy/energy-dispersive X-ray spectroscopy (SEM/EDS), x-ray diffraction (XRD), thermogravimetric analysis (TGA), and transmission electron microscopy (TEM).
View Article and Find Full Text PDFEfficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial.
BMC Med
March 2025
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Department of Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Background: We aimed to evaluate the efficacy and safety of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) plus TPC chemotherapy (NAB-paclitaxel, cisplatin or lobaplatin, and capecitabine) in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) who failed to PD-1 inhibitor-containing regimens.
Methods: In this single-arm, open-label, phase 2 study, RM-NPC patients who failed to at least one line of systemic chemotherapy and anti-PD-1 immunotherapy were enrolled and received cadonilimab plus TPC chemotherapy every 3 weeks for up to 6 cycles, followed by cadonilimab plus capecitabine every 3 weeks for a maximum of 2 years. The primary endpoint was the objective response rate (ORR).
CD44v6-mediated regulation of gastric cancer stem cells: a potential therapeutic target.
Clin Exp Med
March 2025
Faculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology (SUAT), Shenzhen, 518107, Guangdong Province, China.
Gastric cancer is the fourth most common cause of cancer-related deaths globally. Cancer stem cells (CSCs) play an essential role in tumor initiation, development, and chemoresistance. However, the molecular mechanisms that regulate CSC traits in gastric cancer, particularly the role of CD44v6 as a key CSC marker, remain poorly understood.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!